Clinical evaluation of the efficacy of dietary sulforaphane on lipid metabolism in postmenopausal wome
- Conditions
- Mild abnormality of lipid metabolism
- Registration Number
- JPRN-UMIN000022732
- Lead Sponsor
- Department of Obstetrics and Gynecology, Nasu Red Cross Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 40
Not provided
We will exclude outpatients 1) who show the abnormal value of blood lipids (TC:260 mg/dL or more, LDL-C:180 mg/dL or more, HDL-C: less than 30 mg/dL), and then are or will be undergoing treatment for abnormal lipid metabolism 2) who regularly use hormone preparations and hypolipidemic drug, and then are judged unsuitable for this study 3) with serious liver diseases in their life or suspected liver diseases 4) with serious diseases in their life and then judged unsuitable for this study 5) with serious diseases such as heart diseases, kidney diseases, organ damage and diabetes 6) with risk of allergy 7) who habitually consume higher amount of alcohol (> avg 60 g alcohol/day) 8) who participated in other clinical trials within 2 months 9) who are judged unsuitable for this study by principal investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Biomarkers of blood lipids such as TC, LDL-C and HDL-C will be measured as primary endpoint. The changes will be compared within each group and between the treatment groups.
- Secondary Outcome Measures
Name Time Method As secondary endpoints, following items will be evaluated; physical parameters, blood biochemical values, biomarkers of oxidative stress and inflammation, variety and ratio of bacteria in stool (intestinal microbiota)